PEPVERAAUTHENTIC HIGH-QUALITY PEPTIDES
SIGN IN
Mazdutide
CUT · XI

Mazdutide

Asia-trial dual agonist.

From / per milligram
$24$—/mg · 3MG
Sizes available
—
Lab certificate (COA)
Arrives with shipment
View test certificate →

· Research-grade only · Not for human consumption · 21+ ·

What is it

Triple-receptor agonist. China Phase 3 (weight loss and glucose control).

Mechanism · GLP-1 + glucagon + GIP triple-agonist. Innovent Biologics Phase 3 China trials.

Who

Best for. Not for.

Best for

  • Comfortable trying an Innovent / Eli Lilly Phase 3 China-market compound.
  • Want triple-receptor synergy on par with retatrutide globally.
  • Concurrent weight-loss and T2DM goals.

Not for

  • Limited Western clinical data. China NMPA leads; not FDA approved.
  • GLP-1 class warnings.
  • Pregnancy, nursing, or type 1 diabetes.
What it does

Mechanism, dose, ramp, risk.

Mechanism
Dual GLP-1 + glucagon. Phase 3 in China.Source · PEPVERA editorial
Target dose
Research-only protocols.Source · PEPVERA editorial
Ramp
Trial mirrors Retatrutide cadence.Source · PEPVERA editorial
Risks
Limited Western data.Source · PEPVERA editorial
Alternatives

Compared to its siblings.

★ Currently viewing

Mazdutide

Triple-receptor agonist. China Phase 3 (weight loss and glucose control).

Pros

  • · Triple-receptor synergy beyond tirzepatide's dual mechanism.
  • · Includes GIP arm absent in survodutide.
  • · Lower cost than retatrutide.

Cons

  • · Limited Western trial data; evidence is China-led.
  • · No FDA approval, unlike tirzepatide.
  • · Lower-quality Western evidence base than retatrutide.
  • · Less MASH-specific data than survodutide.

Retatrutide

Eli Lilly triple-agonist. Western Phase 2 dataset.

Pros

  • · Western trial data.
  • · Higher-quality evidence.

Cons

  • · Still Phase 2.
  • · Higher cost.

See Retatrutide →

Tirzepatide

FDA-approved dual (no glucagon arm).

Pros

  • · FDA 2022.
  • · Broad long-term dataset.

Cons

  • · Lower efficacy than a triple agonist.

See Tirzepatide →

Survodutide

Dual GLP-1 + glucagon. No GIP arm.

Pros

  • · Strong MASH efficacy.

Cons

  • · Missing GIP. Weaker on weight loss.

See Survodutide →

How we verify

COA per supplier

Published, in-house, or shipment-time

Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.

→ How we verify suppliers→ Refund policy
Fat lossMetabolicGLP-1GlucagonExperimentalresearch-only
Suppliers

Compare 0 suppliers

No verified suppliers yet for this compound.

❄ COLD-CHAIN · 5–9 DAYS

Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.

Before you begin

Risk

Limited Western data. These pass with discipline. They do not pass with bravado.

Source · PEPVERA editorial

Discipline

Trial mirrors Retatrutide cadence.

Source · PEPVERA editorial

Wellness

Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.

Anti-patterns

  • · Do not pair with stimulants late in the day.
  • · Do not break the cycle without a planned taper.
  • · Do not exceed the dose to chase a deeper sleep response.

Crisis

If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.

Dosing protocol

Week 1–2

0.25 mg / wk

Baseline ramp

Week 3–4

0.5 mg / wk

Hold, observe

Week 5–8

1.0–2.0 mg / wk

Ascend

Week 9–12

Research-only protocols.

Terminus

Reconstitution

Draw 20 units.

0.3 mg = 0.20 mL at 1.50 mg/mL. 10.0 doses per vial.

cut · XI

Mazdutide · 3mg